Ann: Alterity Granted U.S. FDA Fast Track Designation for ATH434, page-31

I was thinking the same despite the market being a bit shaky, we've still seen some solid runs lately (ADN springs to mind), so there's definitely still appetite out there. I quickly checked in with ChatGPT for its take on how ATH might react to the Fast Track news:
What Could Happen to ATH?
ATH last traded at $0.009, with a market cap of $85M. Based on historical comparisons:

	% Increase	Implied Price	Implied Market Cap
1	+25%	$0.01125	~$106M
2	+50%	$0.0135	~$127M

A 25–50% move would be typical for a micro-cap biotech if retail momentum kicks in — which often happens after news like this.
⚠️ Caveats

• ATH's illiquidity and high retail ownership could trigger volatile overreactions.
• Gains may not stick unless strong clinical trial data or a partnership follows.
• ATH434 is still in Phase 2, so no guarantees of commercial success just yet.

Final Take:
If the market responds well, ATH could see a short-term pop to around $0.013 — but holding those gains will depend on what comes next.

Curious to see how accurate it is, this is the result after I asked it to give me the typical reaction to this annnouncment.